Longboard Pharmaceuticals (LBPH) Competitors $59.98 0.00 (0.00%) (As of 12/2/2024) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LBPH vs. ROIV, ITCI, RVMD, ASND, LEGN, NUVL, ELAN, LNTH, BPMC, and CYTKShould you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Roivant Sciences (ROIV), Intra-Cellular Therapies (ITCI), Revolution Medicines (RVMD), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Nuvalent (NUVL), Elanco Animal Health (ELAN), Lantheus (LNTH), Blueprint Medicines (BPMC), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Longboard Pharmaceuticals vs. Roivant Sciences Intra-Cellular Therapies Revolution Medicines Ascendis Pharma A/S Legend Biotech Nuvalent Elanco Animal Health Lantheus Blueprint Medicines Cytokinetics Longboard Pharmaceuticals (NASDAQ:LBPH) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends. Do institutionals & insiders believe in LBPH or ROIV? 63.3% of Longboard Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 4.6% of Longboard Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, LBPH or ROIV? Longboard Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Roivant Sciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Do analysts rate LBPH or ROIV? Longboard Pharmaceuticals presently has a consensus target price of $59.56, indicating a potential downside of 0.71%. Roivant Sciences has a consensus target price of $17.93, indicating a potential upside of 45.05%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Longboard Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longboard Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Does the media prefer LBPH or ROIV? In the previous week, Roivant Sciences had 15 more articles in the media than Longboard Pharmaceuticals. MarketBeat recorded 20 mentions for Roivant Sciences and 5 mentions for Longboard Pharmaceuticals. Longboard Pharmaceuticals' average media sentiment score of 1.14 beat Roivant Sciences' score of 1.01 indicating that Longboard Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longboard Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, LBPH or ROIV? Roivant Sciences has higher revenue and earnings than Longboard Pharmaceuticals. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongboard PharmaceuticalsN/AN/A-$54.42M-$2.23-26.90Roivant Sciences$124.79M72.10$4.35B$5.652.19 Is LBPH or ROIV more profitable? Roivant Sciences has a net margin of 3,827.42% compared to Longboard Pharmaceuticals' net margin of 0.00%. Roivant Sciences' return on equity of -14.65% beat Longboard Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Longboard PharmaceuticalsN/A -33.03% -30.90% Roivant Sciences 3,827.42%-14.65%-13.19% Does the MarketBeat Community prefer LBPH or ROIV? Longboard Pharmaceuticals received 12 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 75.00% of users gave Longboard Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLongboard PharmaceuticalsOutperform Votes6375.00% Underperform Votes2125.00% Roivant SciencesOutperform Votes5177.27% Underperform Votes1522.73% SummaryRoivant Sciences beats Longboard Pharmaceuticals on 15 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.Register for the FREE Workshop Now & get $10 in Bitcoin Get Longboard Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LBPH vs. The Competition Export to ExcelMetricLongboard PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.34B$6.68B$5.19B$9.15BDividend YieldN/A8.02%5.76%4.02%P/E Ratio-26.9010.63126.2617.71Price / SalesN/A227.991,182.9172.44Price / CashN/A56.9842.3538.08Price / Book35.925.474.844.98Net Income-$54.42M$152.76M$120.33M$225.13M7 Day PerformanceN/A1.62%0.55%0.79%1 Month Performance0.33%-2.48%0.13%5.51%1 Year Performance1,187.12%28.47%33.76%31.47% Longboard Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LBPHLongboard Pharmaceuticals1.3383 of 5 stars$59.98flat$59.56-0.7%N/A$2.34BN/A-26.9020ROIVRoivant Sciences3.3906 of 5 stars$12.59-0.9%$17.93+42.4%+26.1%$9.16B$129.13M2.23860Analyst RevisionNews CoveragePositive NewsITCIIntra-Cellular Therapies4.7406 of 5 stars$85.610.0%$97.23+13.6%+37.6%$9.08B$464.37M-98.45560Insider TradePositive NewsRVMDRevolution Medicines4.5898 of 5 stars$51.97-10.2%$61.00+17.4%+100.5%$8.74B$742,000.00-14.90443Analyst ForecastAnalyst RevisionHigh Trading VolumeASNDAscendis Pharma A/S3.2198 of 5 stars$133.93-1.6%$191.77+43.2%+24.9%$8.12B$288.08M-16.84640Positive NewsLEGNLegend Biotech2.1875 of 5 stars$43.53+3.5%$81.46+87.1%-32.2%$7.99B$520.18M-44.281,800Positive NewsNUVLNuvalent2.9802 of 5 stars$94.01-2.8%$112.60+19.8%+38.3%$6.68BN/A-27.4840Positive NewsELANElanco Animal Health4.3885 of 5 stars$13.31+0.8%$16.75+25.8%-2.9%$6.58B$4.45B32.559,300Analyst RevisionLNTHLantheus4.441 of 5 stars$89.97+0.8%$125.71+39.7%+22.9%$6.26B$1.30B14.85834Positive NewsBPMCBlueprint Medicines3.5039 of 5 stars$96.43+0.1%$122.11+26.6%+32.5%$6.13B$249.38M-45.68640Insider TradeShort Interest ↓Positive NewsCYTKCytokinetics4.2354 of 5 stars$51.00-1.7%$83.93+64.6%+52.3%$6.02B$3.22M-9.42250 Related Companies and Tools Related Companies ROIV Competitors ITCI Competitors RVMD Competitors ASND Competitors LEGN Competitors NUVL Competitors ELAN Competitors LNTH Competitors BPMC Competitors CYTK Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LBPH) was last updated on 12/7/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Bold Move Could Change the Market ForeverAmerica’s Return to Gold? New economic vision could reshape your entire retirement strategy… Gold Safe Exchange | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longboard Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longboard Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LBPH Stock Alerts